FORCE’s eXamining the Relevance of Articles for Young Survivors (XRAYS) program is a reliable resource for breast cancer research-related news and information. XRAYS reviews new breast cancer research, provides plain-language summaries, and rates how the media covered the topic. XRAYS is funded by the CDC.
Breast cancer survivors
Women under 45
Women over 45
Men with breast cancer
Metastatic breast cancer
Triple negative breast cancer
BRCA mutation carriers
Her2+ breast cancer
Women who take aspirin regularly may have a reduced risk of breast cancer. However, previous studies have reported mixed results—some suggest risk is lowered with aspirin while others do not see a protective effect. Few of these studies have looked at whether this potential benefit of aspirin is linked to specific types of breast cancer. This study found a modest reduction in breast cancer risk for women who took a low-dose aspirin at least three times per week, but only for one subtype of breast cancer. Women who took aspirin were less likely to develop ER/PR-positive/Her2- negative breast cancer, the most common type of breast cancer. This study found no breast cancer risk reduction for women who used regular-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS). (8/29/17)
Whether use of aspirin and other non-steroidal anti-inflammatory medications (NSAIDS) can lower breast cancer risk.
The United States Preventive Services Task Force recommends daily use of low-dose (81 mg) aspirin for cardiovascular disease and colorectal cancer risk reduction. There have been many previous studies examining whether taking aspirin can reduce breast cancer risk. The results of these prior studies have been mixed—some studies claim regular use of aspirin can lower breast cancer risk while others do not report risk reduction. Experts have also speculated about the dose of aspirin needed to decrease breast cancer risk. This study is the first to report that regular use of low-dose aspirin is associated with a reduction in risk of ER/PR-positive and HER2-negative breast cancer. This study supports the need for an additional, larger randomized clinical trial to prove that low-dose aspirin indeed lowers the risk for certain types of breast cancer.
This research study suggests that taking low-dose aspirin at least three times per week modestly lowers a woman’s risk of developing breast cancer, specifically ER/PR-positive/HER2-negative subtype breast cancer. However, it is important to note that this is an observational study and not a clinical trial. While aspirin use was associated with a lower risk of breast cancer, it does not prove that the aspirin caused the lower risk. There may be other reasons why the women in this study who took aspirin had lower risk.
Results of this study are not consistent with those of the Women’s Health Study, the only randomized trial to prospectively look at whether low-dose aspirin reduces breast cancer risk. The Women’s Health Study found no decrease in overall breast cancer for women who took low-dose aspirin every other day regardless of hormone receptor status. More research needs to be done in much larger groups of women to better understand the benefit of regular use of low-dose aspirin on risk for different subtypes of breast cancer. In the meantime, women should talk to their healthcare providers to determine the best way to manage their breast cancer risk.
Breast Cancer News
Daily use of low-dose (81 mg) aspirin is recommended by the United States Preventive Service Task Force to reduce risk of heart disease and colon cancer. There have been many studies evaluating whether aspirin can lower breast cancer risk; however, results have been mixed.
The results of the two meta-analyses suggest that aspirin may reduce risk of specific subtypes of breast cancer.
Christina Clarke and her colleagues from the Cancer Prevention Institute of California and other institutions published research in Breast Cancer Research in May 2017 that adds to the body of literature regarding aspirin’s effect on breast cancer risk. Because few studies have looked at aspirin use and risk reduction of specific breast cancer subtypes based on Her2 status, Clarke and her colleagues prospectively studied whether aspirin can reduce risk of breast cancer overall and by subtype.
Determine whether low-dose aspirin and other NSAIDS lowered breast cancer risk.
The women involved in this study were from the California Teachers Study cohort (CTS), established in 1995-1996. These women were asked to complete a questionnaire that included information on their family history of cancer, other medical conditions, menstrual and reproductive history, self-reported weight and height, living environment, diet, alcohol and tobacco use, physical activity history, and the frequency and duration of prior use of certain medications, including aspirin.
Ten years later, in 2005-2006, the women were asked to complete a follow-up questionnaire about how frequently they use/used aspirin, low-dose aspirin, and other pain-relieving medications. Among the 96,179 participants, 57,164 completed the follow-up questionnaire. During the follow-up period (from the date a woman completed the 2005-2006 questionnaire through December 2012), 1,457 women were diagnosed with invasive breast cancer.
The major limitation of this study is the study design. It is observational, meaning it only observed whether women who took aspirin had a lower incidence of developing breast cancer. Thus, low-dose aspirin use was associated with a lower risk of developing breast cancer, but may not be the cause of that lower risk. The researchers note that there may be some factors affecting the results of their research particularly among women who took three or more tablets of low-dose aspirin each week. For example, women who do this may be generally more health conscious – they may eat healthier and exercise more regularly than women who did not take low-dose aspirin. If this is the case, these women may have lowered their breast cancer risk by diet and exercise versus aspirin. It may also be that the reasons women in this study took aspirin at all were the actual reasons they had lower risk. For example, some women may have taken aspirin to reduce symptoms of arthritis which may be due to lower estrogen levels.
Additionally, this research did not study a representative sample of women. Specifically:
Therefore the results of the study may not apply to all women throughout the United States.
This study suggests that taking low-dose aspirin three or more times per week may lower a woman’s risk for developing breast cancer. These results are consistent with some existing studies but contrary to others. This is the first study to suggest that risk reduction occurs when women use low-dose aspirin and not regular-dose aspirin. This suggestion may reflect frequent use of low-dose aspirin for prevention versus periodic use of regular-strength aspirin taken for pain relief. This study also indicates that low-dose aspirin reduces risk particularly for ER/PR-positive/HER2-negative, the most common type of breast cancer. These results will need to be validated in a larger prospective, randomized trial before they can be universally accepted, especially since they contradict those of a previous
randomized trial, the Women’s Health Study. However, if low-dose aspirin, a widely available, inexpensive medication, was confirmed to be an effective risk reducing strategy for the most common type of breast cancer, the benefit could be extremely significant.
Share your thoughts on this XRAYS article by taking our brief survey
Clarke CA, Canchola AJ, Moy LM, Neuhausen, SL, Chung, NT, Lacey, JV and Bernstein, L. “Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.” Breast Cancer Research. 2017. 19:52
Prior studies referenced in this review
Cancer Risk: Breast Cancer
Risk Management: Breast Cancer Chemoprevention